Skip to main content
. 2022 Jul 7;159(1):65–79. doi: 10.1007/s11060-022-04044-1

Fig. 1.

Fig. 1

Cognitive performance (in percentile ranks) in NeuroCog FX subtests at baseline and follow-up, separated for treatment groups. a Radiotherapy (n = 10). b Chemotherapy (n = 21). c Combined radio-chemotherapy (n = 24). d Watch-and-wait (n = 31). Asterisks indicate statistically significant changes (i.e. improvement) in cognitive performance; * p < 0.05, ** p < 0.01, *** p < 0.001; bars indicate standard error of mean